EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Inhalation of vaccines and antiviral drugs to fight respiratory virus infections: reasons to prioritize the pulmonary route of administration

Rick Heida iD, Henderik W Frijlink, Wouter L J Hinrichs

mBio · 31.10.2023 · 14 (5)

DOI: 10.1128/mbio.01295-23 ↗

Kurz gefasst

Fachartikel in der Zeitschrift mBio, erschienen am 31.10.2023. Verfasst von Rick Heida und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Technology and Biopharmacy, Groningen Research Institute of Pharmacy, University of Groningen , Groningen, The Netherlan…. Hauptthemen laut MEDLINE: Vaccines, Virus Diseases. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 68 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (SNF).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Many of the current pandemic threats are caused by viruses that infect the respiratory tract. Remarkably though, the majority of vaccines and antiviral drugs are administered via alternative routes. In this perspective, we argue that the pulmonary route of administration deserves more attention in the search for novel therapeutic strategies against respiratory virus infections. Firstly, vaccines administered at the viral portal of entry can induce a broader immune response, employing the mucosal arm of the immune system; secondly, direct administration of antiviral drugs at the target site leads to superior bioavailability, enabling lower dosing and reducing the chance of side effects. We further elaborate on why the pulmonary route may induce a superior effect compared to the intranasal route of administration and provide reasons why dry powder formulations for inhalation have significant advantages over standard liquid formulations.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

VaccinesVirus DiseasesHumansAntiviral AgentsAdministration, InhalationAerosols

Stichwörter der Autor:innen

IgASARS-CoV-2aerosolsantiviral agentsdry powder formulationdry powder inhalerinhalationmucosal immunitypulmonary administrationrespiratory virusesspray dryingvaccines

Substanzen

Antiviral AgentsVaccinesAerosols

Autor:innen und Institutionen

  • Department of Pharmaceutical Technology and Biopharmacy, Groningen Research Institute of Pharmacy, University of Groningen , Groningen, The Netherlands.

ORCID-Profile: Rick Heida

Förderung

  • Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (SNF)

Zitieren

APA

Heida, R., Frijlink, H. W., & Hinrichs, W. L. J. (2023). Inhalation of vaccines and antiviral drugs to fight respiratory virus infections: reasons to prioritize the pulmonary route of administration. mBio, 14(5). https://doi.org/10.1128/mbio.01295-23

Vancouver

Heida R, Frijlink HW, Hinrichs WLJ. Inhalation of vaccines and antiviral drugs to fight respiratory virus infections: reasons to prioritize the pulmonary route of administration. mBio. 2023;14(5). doi:10.1128/mbio.01295-23

BibTeX
@article{Heida2023,
  author = {Heida, Rick and Frijlink, Henderik W and Hinrichs, Wouter L J},
  title = {Inhalation of vaccines and antiviral drugs to fight respiratory virus infections: reasons to prioritize the pulmonary route of administration},
  journal = {mBio},
  year = {2023},
  volume = {14},
  number = {5},
  doi = {10.1128/mbio.01295-23}
}
Kostenlos starten →